Article

Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE).

Hôpital Edouard-Herriot, Oncologie médicale, Pavillon E, 5 place d'Arsonval, 69437 Lyon Cedex 03, France.
Critical Reviews in Oncology/Hematology (impact factor: 4.41). 12/2007; 64(2):106-14. DOI:10.1016/j.critrevonc.2007.04.013 pp.106-14
Source: PubMed

ABSTRACT Over the last decades, the development of new drugs has allowed cancer patients to experience several lines of chemotherapy, the objective of which is a long term stabilization of the tumour. The objectives of this work was to delineate a composite index of relative antitumoural efficacy (In-RATE) of a regimen over another, including response rate (RR), median time to progression (TTP) and progression rate (PR). When considering two treatments a and b, the In-RATE was defined as RRa/RRb x TTPa/TTPb x PRb/PRa. Values significantly superior or inferior to 1 reveal an advantage for treatment a or b, respectively. The applicability of the In-RATE to published randomized trials in four frequent tumour types (colorectal, non-small cell lung, advanced ovarian and metastatic breast cancers) was suggested to more precisely distinguish the effects of different drugs, and sometimes to detect a significant difference when the published data did not conclude to statistical difference.

0 0
 · 
0 Bookmarks
 · 
24 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

applicability
 
cancer patients
 
composite index
 
different drugs
 
frequent tumour types
 
last decades
 
metastatic breast cancers
 
non-small cell lung
 
randomized trials
 
relative antitumoural efficacy
 
response rate
 
RRa/RRb x TTPa/TTPb x PRb/PRa
 
TTP